Showing results (221-230 of 297) with videos related to
Sort By:
Pageof 30
Biochemical Pharmacology|September 18, 2023
Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitorsElisa Herraez, Ruba Al-Abdulla, Meraris Soto, et al.Liver International : Official Journal of the International Association for the Study of the Liver|August 2, 2025
Pharmacological Inhibition of c-Jun N-Terminal Kinase Activity Exacerbates Liver Damage in Schistosoma mansoni Infected MiceFrederik Stettler, Lukas Knedla, Maximilian Hagen, et al.Clinical Research in Cardiology : Official Journal of the German Cardiac Society|August 6, 2024
Incremental prognostic utility of congestion markers in cardiac transthyretin amyloidosisSandra Michaela Ihne-Schubert, Caroline Morbach, Vladimir Cejka, et al.Liver International : Official Journal of the International Association for the Study of the Liver|August 4, 2004
Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis CAndreas Geier, Michael Reugels, Ralf Weiskirchen, et al.Journal of Hepatology|December 1, 2012
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infectionMonika Rau, Felix Stickel, Stefan Russmann, et al.Nature Genetics|July 5, 2005
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humansSonja Hillebrandt, Hermann E Wasmuth, Ralf Weiskirchen, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 6, 2025
Diagnostic Performance of [18F]PSMA-1007 PET/CT on Proven PSMA-Positive Hepatocellular Carcinoma: A Prospective Clinical StudyKerstin Michalski, Florian P Reiter, Aleksander Kosmala, et al.Plos One|December 4, 2018
Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patientsMonika Rau, Johannes Schmitt, Thomas Berg, et al.Zeitschrift Fur Gastroenterologie|February 15, 2023
[Intersectoral management of patients with abnormal liver enzymes and non-alcoholic fatty liver disease (NAFLD)]Andreas Teufel, Andreas Geier, Christoph Sarrazin, et al.Journal of Clinical Medicine|April 9, 2024
Cardio-Hepatic Interaction in Cardiac AmyloidosisSandra Michaela Ihne-Schubert, Oliver Goetze, Felix Gerstendörfer, et al.Pageof 30